Rockwell Medical Files 8-K: Other Events & Financials

TL;DR

ROCKWELL MEDICAL (RMTI) filed an 8-K today covering other events and financials. Keep an eye out for details.

AI Summary

On November 13, 2024, Rockwell Medical, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and operational events. Specific details regarding the nature of these events or financial figures were not provided in the excerpt.

Why It Matters

This filing signals to investors that Rockwell Medical is making disclosures about significant company events or financial updates, which could impact the company's stock performance.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report, typically used for material event disclosures, and does not inherently suggest high risk without specific content analysis.

Key Players & Entities

• Rockwell Medical, Inc. (company) — Registrant
• November 13, 2024 (date) — Date of earliest event reported
• 30142 S. Wixom Road, Wixom, Michigan 48393 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — h registered Common Stock, par value $0.0001 RMTI Nasdaq Capital Market Indicate
• $25,000,000 — of an aggregate offering price of up to $25,000,000 of the Company's common stock, par valu

Filing Documents

• tm2428115d2_8k.htm (8-K) — 28KB
• tm2428115d2_ex5-1.htm (EX-5.1) — 7KB
• tm2428115d2_ex5-1img001.jpg (GRAPHIC) — 10KB
• 0001104659-24-117447.txt ( ) — 220KB
• rmti-20241113.xsd (EX-101.SCH) — 3KB
• rmti-20241113_lab.xml (EX-101.LAB) — 33KB
• rmti-20241113_pre.xml (EX-101.PRE) — 22KB
• tm2428115d2_8k_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On October 8, 2024, Rockwell Medical, Inc., a Delaware corporation (the " Company "), filed with the U.S. Securities and Exchange Commission (the " SEC ") a shelf registration statement on Form S-3 (the " New Registration Statement ") to replace the existing shelf registration which was scheduled to expire on October 8, 2024, pursuant to Rule 415(a)(5) under the Securities Act of 1933, as amended. The Prior Registration Statement was deemed terminated upon the effectiveness of the New Registration Statement on October 21, 2024. In connection with the filing of the New Registration the offer and sale of an aggregate offering price of up to $25,000,000 of the Company's common stock, par value $0.0001 per share (the " Common Stock "), pursuant to the Controlled Equity Offering SM Sales Agreement, dated April 8, 2022 (the " Sales Agreement "), by and between Cantor Fitzgerald & Co. and the Company. A copy of the Sales Agreement was previously filed as Exhibit 10.2 to the Company's Annual Report on Form 10-K with the SEC on March 21, 2024. The Company is filing this Current Report on Form 8-K to provide the legal opinion of its counsel, Gibson, Dunn & Crutcher LLP, regarding the legality of the securities covered by the Prospectus Supplement, which opinion is attached hereto as Exhibit 5.1.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Gibson, Dunn & Crutcher LLP 23.1 Consent of Gibson, Dunn & Crutcher LLP (see Exhibit 5.1) 104 Cover Page Interactive Data File, formatted Inline XBRL and included as Exhibit 101 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ROCKWELL MEDICAL, INC. Date: November 13, 2024 By: /s/ Mark Strobeck Mark Strobeck President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR